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3,4-methylenedioxy-N-methylamphetamine (MDMA; also known as "ecstasy") is a 
psychoactive drug that was first synthesized in 1912 by the pharmaceutical company Merck. This 
amphetamine derivative has been investigated for clinical purposes as it has various interesting 
mood-altering properties, although in the 1980s was Schedule-I controlled in the United Kingdom, 
which implies a non-approved medical use, potential for high abuse and illegallity in terms of 
possession. Since MDMA was banned, there has been a campaign to mantain interest in the 
potential therapeutic value of MDMA, including post-traumatic stress disorder (PTSD). PTSD is a 
prevalent and disabling disorder, frequently chronic and associated with significant morbidity, 
poor quality of life, and high personal, social and economic costs. For many patients, the traumatic 
memories are so powerful and distressing that they cannot bare the emotions subsequent to their 
recovery, and therefore find themselves unable to complete the therapy. MDMA has the ability to 
reduce the brain responses to threats, which may allow patients to engage fully in the treatment. 
This work analyzes the latest reports about this treatment and also revise evidence from 
randomized controlled trials (RCTs) for the efficacy of acute and long-term pharmacotherapy for 
PTSD, including the treatment of refractory PTSD with MDMA.  
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La 3,4-metilendioxi-N-metilamfetamina (MDMA; també coneguda com èxtasi) és una 
molècula psicoactiva que va ser sintetitzada per l'empresa farmacèutica Merck l'any 1912. Aquest 
derivat amfetamínic s'ha investigat amb objectius clínics degut a les seves propietats interessants 
d'alteració de l'estat d'ànim. Als anys 80 va ser categoritzat al Regne Unit com a substància de 
categoria 1, "Schedule I", i en conseqüència va definir-se com a substància sense ús mèdic 
aprovat, amb potencial d'abús alt i de possessió il·legal. Des que es va prohibir, hi ha hagut una 
campanya per mantenir interès en el seu potencial terapèutic, incloent el tractament del trastorn 
d'estrès post-traumàtic (TEPT). El TEPT és un trastorn prevalent i inhabilitant, freqüentment 
crònic i associat a una elevada morbiditat, qualitat baixa de vida i costs elevats personals, socials 
i econòmics. Per molts pacients, les memòries de la situació traumàtica que ha desencadenat en 
la malaltia són tan fortes i desagradables que no poden tolerar les emocions resultants de la 
recuperació, i per tant no poden completar la teràpia. L'MDMA té l'habilitat de reduïr les respostes 
neuronals a aquestes amenaces, fent que els pacients puguin afrontar el tractament de forma 
completa. Aquest treball analitza les últimes informacions sobre aquest tractament i també revisa 
l'evidència d'assajos clínics randomitzats per l'eficàcia de la farmacoteràpia a llarg plaç per el 
TEPT, incloent el tractament de TEPT refractari amb MDMA. 






2. AREAS INCLUDED IN THE PROJECT 
 
The main area of this undergraduate dissertation is pharmacology, the area of biomedical 
science that studies how medicines and other drugs work and are processed by the body, the 
drug action. Pharmacology is crucial for discovering new medicines to help fight diseases and it 
is essential for improving the effectiveness and reducing the unwanted side effects of medicines, 
understanding why individuals differ in the way they respond to certain drugs, and why some 
others cause addiction. This project focuses on the use of MDMA as a therapeutical option for 
diseases, in particular post-traumatic stress disorder, and move it away from the recreational 
night scene that is related to.  
On the one hand, toxicology is the second area included because it is the field of science 
that helps to understand the harmful effects that MDMA can have on people, animals, and the 
environment. It is important to keep in mind that not everyone will respond to substances in 
exactly the same way and that the dose of the chemical or substance a person is exposed to is 
another relevant factor, and this is why toxicology is important in this project.  
On the other hand, the third area includes Physiology and Pathophysiology, because of the 
study of the functional changes associated with or resulting from disease or injury, the post-



























In this report, the substituted phenethylamine 3,4-methylenedioxy-N-methylamphetamine 
(MDMA) and post-traumatic stress disorder (PTSD) will be properly studied. MDMA is a commonly 
used illicit drug and is the sole or one of the ingredients in "ecstasy". It was synthesized and 
patented by Merck in 1912 but not originally intended for human consumption, because it was 
made as a precursor in a new synthesis process for hemostatic substances. It was tested in 
animals and interrogation enhancement studies were carried out by the United States (US) 
military starting in the 1950s (1). In 1985, the Drug Enforcement Agency (DEA) labeled it a 
Schedule I drug, meaning no approved medical use, high abuse potential and illegal to posses. 
Before its placement into the most restrictive category of drug regulation internationally, 
uncontrolled published reports suggested that MDMA, when administered in conjunction with 
psychotherapy, could yield substantial benefits for those afflicted with a variety of disorders (2). 
MDMA is hypothesized to support and enhace psychotherapy by increasing the subject's access 
to emotionally-upsetting material, modulating the associated level of arousal and strengthening 
the therapeutic alliance (3). It produces unique changes in emotions in humans through a 
complex combination of pharmacological effects. MDMA is not the only monoamine releaser with 
particularly prominent effects on serotonin, but it also elevates serum oxytocin, which is a 
neuropeptide believed to play a role in affiliation and bonding in mammals (4). Brain imaging 
studies show there is reduced amygdalar activity after MDMA administration, plus changes in the 
response to angry and happy facial expressions (5). These findings suggest that MDMA may 
enhace the therapeutic alliance by increasing the likelihood of detecting positive expressions and 
finding them rewarding, while at the same time reducing the chance of excessive reactivity to 
fleeting or unintended expressions of anger or disapproval. Recent investigations support that 
there are positive effects on post-traumatic stress disorder (PTSD) symptoms severity by 
increasing self-acceptance, promoting interpersonal trust with therapists and catalyzing the 
effective processing of emotionally-distressing material, but due to its drug scheduling, this is 
difficult to conduct (6). PTSD is a prevalent disorder that can be a chronic, severely disabling 
condition causing sustained loss of functionallity, accompanied by high rates of medical and 
psychiatric co-morbidity and risk of suicide. Recognition of neurobiological abnormalities 
associated with this condition suggests the potential efficacy of medication in its treatment. To 
date psychotherapy has been the mainstay of treatment for PTSD and has a larger effect size 
than pharmacological treatment. Cognitive behavioral therapies, particularly prolonged exposure 
and cognitive processing therapy, are considered among the most effective psychotherapies. 
Other methods such as psychodynamic therapy and eye movement desensitization and 
reprocessing (EMDR) have also proved to be effective in treating some aspects of PTSD symptoms 
(7). Due to the rate of treatment resistance, the need for research into a wider array of more 






The main objective for this research is showing the current status of the therapy of PTSD 
with MDMA, which could be a promising treatment for patients with PTSD.  
To achieve this goal there are three specific steps which will be crucial to define de success 
of this research: 
1. Study of the molecule of MDMA, and its general characteristics evaluating the 
safety and efficacy, in consideration of the studies that has been done; 
2. Discuss the pharmacological treatments approved for PTSD and the efficacy of 
different medications in treating PTSD; 













5. MATERIALS AND METHODS 
 
 
In this undergraduate dissertation I synthesize and critically analyze the information I have 
found in the literature about the use of MDMA in the treatment of PTSD, mainly based on the 
works by Michael Mithoefer and MAPS organization. I have made a literature review using mainly 
the free resoure Pubmed®. PubMed® has provided me free access to MEDLINE®, the National 
Library of Medicine® (NLM®) journal citation database. There is another health-related database 
I have used, the Cochrane Library, a collection of databases that bring together research on the 
effectiveness of healthcare treatments and interventions.  
This bibliographic review has been performed through the research of significant keywords: 
MDMA, posttraumatic stress disorder, PTSD, combat disorders, psychedelics, psychotherapy, drug 
abuse, treatment efficacy and ecstasy. More than 200 results were obtained from all types of 
articles, and the review was not limited by year of publication or text availability, although the 
language of the studies was filtered to English or Spanish. After the initial search, about 100 
studies were excluded because they were to not be of relevance for the purpose of the review. 
The bibliographic references of the selected articles were also analyzed in order to include other 
potentially interesting articles for the review.  









6. GENERAL INTRODUCTION TO MDMA 
 
6.1. HISTORY OF "ECSTASY" 
Ecstasy is the popular or “street” name for the substance identified chemically as N-methyl-
3,4-methylenedioxy-amphetamine or 3,4-methylenedioxy-N-methylamphetamine. The initial 
letters of the major portions of the latter name (Methylenedioxy-Methamphetamine) give rise to 
the acronym MDMA, by which this substance is commonly designated in the clinical and research 
literature. It is a synthetic drug that alters mood and perception, chemically similar to both 
stimulants and hallucinogens, producing feelings of increased energy, pleasure, emotional 
warmth, and distorted sensory and time perception. It is a ring-substituted amphetamine 
derivative structurally related to the hallucinogenic compound mescaline, found in the peyote 
cactus, to amphetamine (Amph) and phenylethylamine derivatives such as methamphetamine 
(Meth), and to the monoamine neurotransmitter serotonin (5-HT) (Figure 1), acting MDMA and 
other Amph derivates as substrate-type releasers binding to the plasma monamine transporters. 
Figure 1. Chemical structures of MDMA and related amphetamines (8) 
There is a closely related compound, N-ethyl-3,4-methylene-dioxyamphetamine (MDEA), 
that differs from MDMA only in having a 2-carbon ethyl group rather than a 1-carbon methyl 
group, attached to the nitrogen atom of the amphetamine structure.  
MDMA was first synthesized and patented in 1912 by the German pharmaceutical company 
Merck under the name of "methylsafrylamin". Many times it has been written erroneously that 
Merck had the intention of using therapeutic MDMA as an appetite supressor. Instead, the 
company was trying to evade an existing patent for the synthesis of a clotting agent called 
"Hydrastinin" held by the German competitor Bayer/Elberfeld, being methylsafrylamin a precursor 




For the next 15 years MDMA was not mentioned and in 1927, Merck's laboratory 
pharmacologically tested it for the first time, transforming MDMA from a free base to a 
hydrochloride salt for the testing. MDMA was as effective as ephetonine, a substance Dr Max 
Oberlin was interested in finding similar structures, at vascular smooth muscle tissue and stronger 
at the uterus. Oberlin concluded that the substance did not have "pure sympathetic effects" (9). 
The toxicology of MDMA was examined in 1953 with other similar compounds at the 
University of Michigan in a classified research program sponsored by the USA military (1). In 
1959, Merck's chemist Dr Wolfgang Fruhstorfer worked with MDMA and similar substances 
because he was interested in the production of new stimulants. There was no indication of MDMA 
testing in humans until 1960 (10). Then in 1978, Alexander Shulgin, a californian chemist, 
synthesized and tested the drug and was the first one to describe that MDMA was a psychoactive 
drug in humans. In fact, he had synthesized MDMA for the first time in 1965 and sometimes he 
is called erroneously the "father" of MDMA (11). He presented the drug to professional therapists 
as a valuable adjunct to psychotherapy in therapeutic settings. By the early 1980s, over a 
thousand private psychotherapists in the USA were using MDMA in their clinical practice, because 
it was believed to increase patient self-esteem and facilitate therapeutic communication (10). 
Meanwhile, in 1977, the UK classified MDMA as a class A drug, meaning it is illegal to possess, 
sell, or give away. In the USA, MDMA became a Schedule I controlled substance in 1985 due to 
its high abuse potential, lack of clinical application, lack of accepted safety for use under medical 
supervision, and evidence that could be neurotoxic. This classification was severely critisized by 
some psychotherapists who realized that their research and medical use of MDMA could not 
continue.  
6.2. DRUG ABUSE OF "ECSTASY" 
The abuse of MDMA started in the USA the early 1980s and became popular in the streets 
as a "fun drug" that was "good to dance". In San Francisco, drug dealers sold MDMA under the 
name of "ecstasy", which they invented for commercial purposes (1). Moreover, its fame spread 
across the Atlantic to Europe and consequently to the rest of the world. Nowadays, The 
Netherlands and Belgium are the main illegal manufacturers by clandestine labs with the 80% of 
the total production. It is commonly consumed on weekends in warm crowded environments and 
combined with dancing.  
After cannabis, ecstasy is the second most widely abused illegal drug in Europe, mostly 
sold and consumed orally in the form of tablets, which frequently contain symbols and are 
colored, though some swallow it in liquid form or snort the powder. Supposedly the tablets are 
pure, but much of them contain additives such as cocaine, ketamine, methamphetamine, 
ephedrine or synthetic cathinones. These substances may be dangerous when combined with 
MDMA and people may be putting themselves at even high risk for harmful health effects. 
However, the latest reports suggest that purity levels of "ecstasy" tablets, in terms of MDMA 




In assessments of single MDMA, most products contained 73-89 mg of MDMA but the range 
went from 20 mg up to 152 mg MDMA.  
The risk of adverse events for a single tablet or powder packet of MDMA is not a precise 
science due to the inability to assure purity, potency, unadulteration, and stability of products 
(12). The risk of death from each single use of MDMA has been estimated between 1 in 20,000 
and 1 in 50,000 (13). In the EU, the European Monitoring Centre on Drugs and Drug Addiction 
estimates that more than one million adults take "ecstasy" every month. Based on general 
population surveys, it has been estimated that almost 8.5 million Europeans have tried "ecstasy", 
and almost three million have used it in 2005 (14), and there is a clear pattern of gradually rising 
over the past years.  
6.3. PHARMACOLOGY OF MDMA 
MDMA and other ring-substituted amphetamine derivatives affect peripheral and central 
nervous system (CNS) functions by acting mainly on the monoaminergic system, inhibiting the 
following monoamine transporters: serotonin transporter (5-HTT), noradrenalin transporter 
(NAT), and dopamine transporter (DAT). It has been studied the mechanism in cultured intestinal 
cells, expressing the human transporters, and the potency order of potencies for MDMA to inhibit 
the monoamine transporters was NAT>5-HTT>DAT (15). In intestinal cells expressing the mouse 
transporter, the order of potencies for MDMA to inhibit the monoamine transporters was 5-
HTT>NAT>DAT, which is in accordance with the data obtained in rats (15). In rat synaptosomes, 
it was found that the rank potency order of MDMA to inhibit monoamine transporters was 5-
HTT>NAT>DAT. The rank order of potencies for MDMA inhibition of the uptake of the three 
monoamine transporters of humans, rats, and mice in comparison with (+)-amphetamine is 
shown in Table 1.  
Table 1. ()-MDMA and (+)-Amph potencies to inhibit the human, rat, and mouse 5-HTT, DAT and NAT 
transporters based on the Ki values (equilibrium dissociation constants) 
Drug 
(substance) 
Experimental model 5-HTT Ki (nM) DAT Ki (nM) NAT Ki (nM) 
(+)-Amph 
Cloned human transporters1 38,463,84 0,640,14 0,070,01 
Cloned mouse transporters1 23,821,71 0,560,11 0,120,02 
Rat synaptosomes2 3,830170 346 38,91,8 
()-MDMA 
Cloned human transporters1 2,410,73 8,291,67 1,190,13 
Cloned mouse transporters1 0,640,05 4,870,65 1,750,51 
Rat synaptosomes2 23813 1,57259 46218 
1Data from Han et al. (2006) (15) 




Data show that the major consequence of the methylenedioxy ring introduction in the 
molecule is the substantial increase of MDMA's potency to inhibit 5-HTT while reducing its 
potencies to inhibit DAT and NAT when compared to methamphetamine (Meth) or amphetamine 
(Amph). This brings the Ki values for all three monoamine transporters to a close range. 
Consistent with in vitro results, in vivo microdialysis experiments in the rat demonstrate that 
MDMA increases exracellular 5-HT and DA levels in the brain, with effects on 5-HT being greater 
in magnitude.  
MDMA acts as a substrate-type releaser, like other amphetamine derivatives. They bind to 
the plasma membrane monoamine transporters, being transported and translocated into the 
cytoplasm, although at high concentration it may also enter by diffusion, stimulating 
neurotransmitter release via the transporter. Specifically concerning MDMA-induced 5-HT 
neurotransmitter release, MDMA produces an acute and rapid enhacement in the release of 5-HT 
from the storage vesicles, possibly by entering the vesicles via the vesicular monoamine 
transporter (VMAT) and depletes vesicular neurotransmitter stores via a carrier-mediated 
exchange mechanism. MDMA also inhibits tryptophan hydroxylase (TPH), the rate-limiting 
enzyme for 5-HT synthesis. In addition, MDMA might also increase extracellular levels of 
monoamines by partially inhibiting brain monoamine oxidase (MAO) activity, mainly MAO-B 
located in the outer membrane of the mitochondria of serotoninergic neurons. MAO is the enzyme 
responsible for 5-HT degradation (17). Due to the increase in the free cytoplasmatic pool of 5-
HT, MDMA promotes a rapid release of intracellular 5-HT to the neuronal synapse via reversal of 
the 5-HTT activity. The hallucinogenic properties of MDMA are due to the agonism at the 5-HT2A 
receptor. Like other hallucinogenic compunds, MDMA was found to possess an affinity for the 5-
HT2 receptor located in rat and human cortical neurons with an estimated affinity Ki= 5M, likely 
through the 3,4-methylenedioxy ring (18).  
In the rat, MDMA stereoisomers are substrates for 5-HTT, NAT, and DAT, with (+) isomers 
exhibiting greater potency as releasers. In particular, (+) isomers of MDMA and MDA (another 
drug of abuse and major MDMA metabolite) are much more effective DA releasers than their 
corresponding (-) isomers. When compared to amphetamine and methamphetamine, (+)-MDMA 
induce the release of 5-HT about ten times more potently than (+)-Meth, whereas (+)-MDMA 
release DA about six times less potently than (+)-Meth (16). This causes an elevation of mood 
and increased energy while also causing the secretion of numerous hormones including cortysol, 
oxytocin, and antidiuretic hormone. Cortisol concentrations significantly increase by 100-150% 
from baseline levels with MDMA ingestions of 0.5 and 2.5 mg/kg of body weight in the absence 
of physical exertion (19). When combined with hot temperatures and physical exertion while 
dancing, two usual characteristics when the drug is taken, cortisol concentrations significantly 






6.4. EFFECTS OF OXYTOCIN ON EMOTIONAL PROCESSING 
Oxytocin is becoming increasingly established as a prosocial neuropeptide in humans with 
therapeutic potential in treatment of social, cognitive, and mood disorders. One line of evidence 
suggests that MDMA produces the effects of increasing feelings of empathy by releasing this 
peptide in humans, involved in social bonding, in addition to its effects on dopamine, serotonin, 
and noradrenalin in the brain. However, the potential of oxytocin as a general facilitator of human 
learning and empathy is unclear. Down below there are explained different studies that had been 
done to describe the prosocial effects of MDMA and his relationship with oxytocine.  
In animals, it has been demonstrated that MDMA increased social interaction in Wistar rats 
meeting for the first time (21). This was predominantly due to an increase in adjacent lying 
behaviour, where rats lie together for prolonged periods of time. This effect of MDMA was 
reversed by coadministration of the 5-HT1A receptor antagonist N-N-[2-[4-(2-methoxyphenyl)-1-
piperazinyl]ethyl]-N-2-pyridinylcyclo-hexanecarboxamide maleate salt (WAY 100,635) (22). In 
this study there were included the emergence and elevated plus-maze tests, social interaction, 
cat odor avoidance and footshock-ultrasonic vocalizations. The results showed that MDMA 
increased anxiety-related behaviours in the emergence and elevated plus-maze tests at all dose 
levels (0, 1.25, 2.5 and 5 mg/kg of MDMA). The 5 mg/kg dose of MDMA reduced significantly the 
time spent in close proximity to an anxiogenic cat odor stimulus. The 5 mg/kg dose also 
significantly reduced footshock-induced ultrasonic vocalizations. In the social interaction test, 
MDMA decreased agressive behaviours at all doses tested, while the highest dose (5 mg/kg) also 
significantly increased the duration of social interaction. These results indicated that MDMA has 
both anxiogenic and anxiolytic effects depending upon the test situation employed, so it has a 
dual effect (22). On the other hand, in rats, MDMA activates the paraventricular nucleus (PVN) 
and supraoptic nucleus (SON) of the hypothalamus, where the cell bodies of brain oxytocinergic 
neurons are located. The magnitude of this SON activation is greater when MDMA is administered 
at high ambient temperatures (23). 
In humans, MDMA increases plasma levels of oxytocin, and these increases are correlated 
with feelings of sociability. Single doses of intranasal oxytocin can also produce prosocial, 
anxiolytic, and affiliative effects in healthy adults. For example, oxytocin has been shown to 
increase trust and generosity (24), reduce responses to social stressors, increase positive 
communication, and, like MDMA, enhace recognition of positive emotional states. The conditions 
under which oxytocin enhaces, or impairs, social interaction remain to be determined. Inspection 
of the literature, reveals that the effects of oxytocin in the social domain are often weak and/or 
inconsistent. Other studies failed to detect prosocial effects of oxytocin, and indeed, found that 
it can produce antisocial effects such as feelings of envy and mistrust (5). The reasons for the 
differences are not known, but may include characteristics of the subjects samples (e.g. age, 
gender, and hormonal state) or testing environment (e.g. outcome measures used, social and 




Nevertheless, similars patterns of prosocial effects produced by MDMA and intranasal 
oxytocin contribute to the prosocial effects of MDMA. There is a study that investigated the acute 
effects of MDMA and oxytocin on social and emotional processing in the same healthy human 
volunteers to examine these patterns of behaviour (4). In this study, it was tested the subjective, 
cardiovascular, and behavioural effects of oral MDMA (0.75 and 1.5 mg/kg) and intranasal 
oxytocin (20 and 40 IU) in healthy young adults (N=65; 25 female, 40 male), with light-to-
moderate past MDMA experience. The study used a within-and-between-subjects, double-blinded 
design in which subjects received two doses of MDMA, one dose of oxytocin, and placebo.  
The results confirmed and extended previous reports on the prosocial effects of MDMA and 
intranasal oxytocin as it is showed in Figure 2. MDMA dose-dependly increased subjective feelings 
of friendliness and sociability and the larger dose (1.5 mg/kg) increased desire to socialize with 
others. Additionally, the larger MDMA dose decreased recognition of negative emotional faces, 
supporting previous evidence that the drug's prosocial behavioural effects might be partially 
explained by a decreased capacity to perceive negative emotional states in others. Intranasal 
oxytocin produced small increases in self-reported sociability but, in contrast to MDMA, oxytocin 
(40 IU) enhaced recognition of negative emotional faces suggesting that MDMA- and oxytocin-
related effects are not synonymous. Overall, these data are consistent with previous reports of 
the prosocial effects of MDMA (25) and extend these earlier findings by demonstrating modest 
correlations between the effects of MDMA and oxytocin in the same individuals.  
In conclusion, MDMA dose-dependently increased subjective ratings of sociability and 
"positive mood". The drug increased ratings of drug liking as well as feelings of friendliness, 
insightful, and sociable. The drug also increased several "negative" subjective ratings such as 
drug dislinking, and feelings of anxiety and loneliness. This mixed profile of both positive and 
negative subject effects is consistent with the purportedly low abuse potential of MDMA relative 
to other amphetamines (25). 
Intranasal oxytocin also increased subjective feelings of sociability and some measures of 
positive mood. Interestingly, the finding that the lower oxytocin dose produced greater effects 
on subjective feelings of sociability is consistent with previous studies indicating that the effects 
of oxytocin are non-linear. The full profile of subjective and behavioural effects of oxytocin 
remains to be determined. There were also qualitative differences in the drug effects: MDMA 
increase heart rate, blood pressure, and objective feelings of anxiety, whereas oxytocin did not 
affect cardiovascular measures and the lower dose (20 IU) reduced anxiety. These differences 










Figure 2. Results from the study by Kirkpatrick et al. (2014) showing: 
 Top panels: selected mean scores on subjective ratings following administration of MDMA or placebo as a 
function of dose and time. An * indicates 1.5 mg/kg MDMA significantly differents from placebo (p<0.05). 
A  indicates 0.75 mg/kg MDMA significantly different from placebo (p<0.05). A + indicates 1.5 mg/kg 
significantly different from 0.75 mg/kg MDMA (p<0.05). Bottom panels: Selected scores on subjective 
ratings following administration of oxytocin or placebo as a function of dose and time. An * indicates 20 IU 
oxytocin significantly different from placebo (p<0.05). A  indicates 40 IU oxytocin significantly different 
from placebo (p<0.05). Error bars represent one SEM. (4) 
6.5. PHARMACOKINETICS 
MDMA has a unique pharmacokinetic and drug interaction profile. First of all, MDMA and 
related amphetamine compounds are weak bases with pKa values around 9.9, low molecular 
weigh, low protein binding (around 20%), and high volume of distribution (26). These properties 
confer easy diffusion across cell membranes, lipid layers, and to tissues or biological matrices 
with a more acidic pH compared to blood. MDMA in humans is well abosorbed when taken orally 
in the form of tablets, and maximum concentration (Cmax) appears at 1.5-3 h (27). After the 
administration of five different doses of MDMA (50, 75, 100, 125 mg), it has been seen that the 
Cmax and area under the curve (AUC) for 24h increased according to the administered dose. 
Meanwhile, for the 150 mg dose, the increase in MDMA kinetic parameters was not proportional 
to the dose, which clearly implies nonlinear pharmacokinetics (27). 
Similarly to humans, the nonlinear pharmacokinetics of MDMA can also be found in rats. 
For instance, MDMA concentrations in the rat brain increase nonlinearly with the dose (28). In 
Figure 3, parallel MDMA concentration-time curves in plasma and brain according to the dose 














Figure 3. (+)-MDMA concentration time-curves in the plasma and brain as a function of the (+)-MDMA 
dose given to Sprague-Dawley rats. MDMA concentrations rise in a nonlinear manner with the increase of 
MDMA dose. The xpected brain concentrations of MDMA, assuming a linear trend of concentrations with 
increasing doses, would be much lower than the ones actually found (28) 
Several studies have been performed to evaluate humans pharmacokinetics of MDMA in 
controlled settings. In a randomized, double blind, crossover study (n=10), subjects were given 
MDMA 100 mg or MDMA 50 mg followed by 100 mg 2 hours later with pharmacokinetics assessed 
over 50 hours and dynamics assessed over 6 hours (3). There were elevations in maximal plasma 
concentrations (Cmax) and area under the curve (AUC) with the higher vs. lower dose but no 
changes in other pharmacokinetic parameters. Physiological measures were recorded, and the 
average peak systolic and diastolic blood pressure differences from baseline were 48.8 and 
148.9% greater over 6 hours with higher vs. lower dose MDMA (p<0.01 for both). While not 
statistically significant, the average temperature difference from baseline comparison was 222% 
greater with higher vs. lower dose MDMA and the temperature difference between groups was 
significantly greater at the 2.3, 2.6, and 3.0 hour individual time point comparisons, so the 
increase in temperature was higher after repeated MDMA administration in comparison with single 
dose. Importantly, no significant changes were seen between groups in the 6 hour Addiction 
Research Center Inventory (ARCI) scales assessing euphoria or stimulant effects (19.4  12.4 vs. 
16.8  1.03, p=NS) but there was a 71.9% increase in the difference from baseline comparison 
for the average measures of dysphoria with higher vs. lower dose MDMA use (9.0  4.3 vs. 5.2  
4.8, p=0.007). Furthermore, visual changes in color were decreased over 6 hours by 59.3% with 
the higher vs. lower dose MDMA (7.7  12.1 vs. 18.9  22.7, P=0.04).  
This phenomenon of higher plasma concentrations without commensurate increase in 
positive psychological effects is attributed to a tolerance phenomenon. Given the dose dependent 
increases in blood pressure and temperature with tolerance to the desirable effects of MDMA, 
overdosing to try and overcome tolerance is concerning.  
6.6. METABOLIC PATHWAYS AND DRUG INTERACTIONS 
MDMA is metabolized mainly in the liver through cytochrome (CYP), mostly CYP2D6, 




MDMA metabolites, showed in Figure 4, are primarily cleared by CYP isoenzymes, catechol-O-













Figure 4. Metabolic degradation of MDMA and its metabolites (30) 
CYP2D6 enzymes show genetic polymorphism and depending on the polymorphism and 
the number of alleles it impacts, can alter their ability to metabolize medications. Drugs that 
reduce CYPD26 activity such as paroxetine, reboxetine, duloxetine, and fluoxetine increase MDMA 
Cmax approximately 20-30%. However, these agents reduce the desirable effects and the risk of 
adverse events with MDMA. In a randomized, double-blind, placebo controlled crossover trial, the 
interaction between duloxetine and MDMA was explored (31). When people were pretreated with 
duloxetine and then ingested MDMA, it significantly attenuated the pharmacologic effects of 
increased well-being, emotional excitation, and extroversion versus MDMA alone. Mechanistically, 
duloxetine therapy attenuated binding of MDMA to NAT and 5-HTT. This is similar to more limited 
data showing that paroxetine and citalopram can also attenuate the blood pressure and heart 
rate effects of MDMA (32). MDMA is a potent CYP2D6 inhibitor and autoinhibitor. A single dose 
can inactivate 75% of CYP2D6 activity within an hour and it takes approximately 2 days to regain 
50% of the function and up to 10 days to fully regain function from its isoenzyme. MDMA inhibits 
its own metabolism, increasing subsequent plasma concentrations, especially when used more 
than weekly.  
On the one hand, ritonavir, a potent CYP3A isozyme and modest CYP2D6 inhibitor, has 
been found to increase MDMA concentrations from standard dosing (50-180 mg) to well above 
1,000 ng/mL (usual Cmax 200-300 ng/mL) (33). On the other hand, COMT is an enzyme available 
in a soluble and membrane bound form that degrades biological amines, and COMT inhibitors will 
not impact the metabolism of MDMA, and prevents the breakdown of the HHMA and HHA 
metabolites. In humans, the urinary recovery of HHMA conjugates are two-fold higher in subjects 




7. POST-TRAUMATIC STRESS DISORDER 
 
7.1. INTRODUCTION TO POST-TRAUMATIC STRESS DISORDER 
It is estimated that as many as 80-100% of all people are exposed to traumatic events 
during their lifetimes (34). Depending on the nature of the trauma, approximately 5-9% of the 
general population go on to develop post-traumatic stress disorder (PTSD). 
PTSD is a psychiatric disorder that can occur in people who have experienced or witnessed 
a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, rape 
or other violent personal assault. People with PTSD continue to have intense, disturbing thoughts 
and feelings related to their experience that last long after the traumatic event has ended. They 
may relive the event through flashbacks or nightmares; they may feel sadness, fear or anger; 
and they may feel detached or estranged from other people. Thereby, frequently becomes chronic 
and associated with significant morbidity, poor quality of life, and high personal, social and 
economic costs. It has been estimated that the US economy alone loses of 3 billion dollars 
annually due to PTSD-related loss in productivity (35). 
A diagnosis of PTSD requires exposure to an upsetting traumating event. However, 
exposure could be indirect rather than first hand. For example, PTSD could occur in an individual 
who learns that a close family member or friend has died accidentally or violently. In the absence 
of scientific understanding of the pathophysiologic processes involved in PTSD development, the 
"gold standard" for defining it has been expert consensus as reflected in Diagnostic and Statistical 
Manual of Mental Disorders (DSM), published by the American Psychiatric Association (APA). 
These criteria have changed as clinical perspectives and scientific understanding have evolved. 
Despite periodic changes, there has been consistent agreement on three sets of symptom clusters 
considered characteristic of PTSD: the intrusive, avoidant and hyperarousal clusters.  
1. The intrusive cluster encompass unwanted and repeatedly re-experienced memories, 
sensations or dreams associated with the trauma. Flashbacks may be so vivid that people 
feel they are re-living the traumatic experience or seeing before their eyes. 
2. The avoidant is about behavioral avoidance of trauma reminders, that may include 
avoiding people, places, activities, objects and situations that bring on distressing 
memories. People may try to avoid remembering or thinking about the traumatic event. 
They may resist talking about what happened or how they feel about it. 
3. The excessive physiological arousal and reactive symptoms may include being irritable 
and having outbursts of anger; behaving recklessly or in a self-destructive way, both in 
response to trauma cues or independently, for example because of sleep problems. 
These core clusters have been embraced in DSM III, IV, and 5, but other symptoms or 
criteria have been added (negative affect or reckless behavior in DSM-5), deleted (trauma outside 




Many people who are exposed to a traumatic event experience symptoms like those 
described above in the days following the event. For a person with PTSD, however, symptoms 
last for more than a month and often persist for years. Many individuals develop symptoms within 
three months of the trauma, but can appear later. PTSD often occurs with other related 
conditions, such as depression, substance abuse, memory problems and other physical and 
mental health problems. Shifting criteria create scientific challenges to sample homogeneity 
across time and undermine clinical efficacy when targets for intervention are imprecise and 
continuously moving.  
Not everyone who experiences trauma develops PTSD, and not everyone who develops 
either requires psychiatric treatment. For some people, symptoms of PTSD subside or disappear 
over time. Others get better with the help of family, friends or clergy. But many people with PTSD 
need professional treatment to recover from psychological distress that can be intense and 
disabling. That distress is not the individual’s fault, and PTSD is treatable. 
7.2. PATHOPHYSIOLOGY 
An inflexibility of the autonomic nervous system (ANS) may be the underlying mechanism 
for the increased morbidity that occurs with PTSD. There are psychophysiological indices of ANS 
function that show abnormal peripheral function, in reaction to trauma exposure, for example 
heart rate variability (HRV). HRV was measured in 459 middle-aged veteran male twins showing 
that combat exposure and current PTSD were associated with measures of autonomic inflexibility 
previously shown to have prognostic significance (36). 
PTSD is also associated with exaggerated catecholamine response to trauma cues and 
elevated levels of NA and decreased levels of cortisol. It was shown that patients with current 
PTSD had significantly higher NA secretion compared to those without PTSD (37). Furthermore, 
patients in the lifetime PTSD group exhibited lower cortisol values compared to those without 
PTSD. Participants who never had PTSD showed the lowest NA and the highest cortisol values 
(37). Additional peripheral biological abnormalities linked include alterations in serotonin systems, 
dehydroepiandrosterone (DHEA) (38), neuropeptide Y (39), endocannabinoids (40) and 
endogenous opioids (41). It has been suggested that alterations in NA and 5-HT may have 
relevance to symptoms commonly seen in survivors with PTSD, including hypervigilance, 
exaggerated startle, irritability, impulsivity, aggression, intrusive memories, depressed mood, and 
suicidality (42). 
Genetic work is rapidly expanding, and has identified PTSD-linked polymorphisms in the 
next genes: 
• FKBP5: four SNPs of the FKBP5 gene interacted with severity of child abuse as a 
predictor of adult PTSD symptoms (43). 
• CRHR1: there is a role of CRHR1 gene in the stress response following potentially a 




• ADRB2: ADRB2 SNPs are strongly associated with the development of PTSD symptoms 
in persons with a history of childhood adversity (45). 
• COMT: the COMT gene is associated with anxiety disorders, psychosis, depression, and 
other conditions involving catecholamine pathway regulation (46). 
7.3. TREATMENT 
Psychiatrists and other mental health professionals use various effective methods to help 
people recover from PTSD. Both talk therapy (psychotherapy) and medication provide effective 
evidence-based treatments for PTSD. One category of psychotherapy, cognitive behavior 
therapies (CBT), is very effective. Cognitive processing therapy, prolonged exposure therapy and 
stress inoculation therapy are among the types of CBT used to treat PTSD. There is a good 
amount of evidence that prolonged exposure therapy is an effective treatment for PTSD (47) and 
it is a first-line treatment recommended in guidelines world-wide. Nevertheless, not all patients 
benefit from exposure therapy as clinical trials have shown. Approximately 50% of patients lose 
their PTSD diagnosis after exposure therapy and that proportion of patients achieving complete 
remission is even smaller (2). Is an attempt to improve treatment efficacy, some researchers 
added other psychological interventions to exposure therapy, such as cognitive restructuring or 
imaginal rescripting. Although some studies found support for beneficial effects, overall the effect 
sizes did not exceed those of stand-alone exposure therapy in a clinically significant way. 
Another way to improve treatment efficacy that is commonly seen in clinical care is the 
combination of exposure therapy and pharmacological treatment such as antidepressant 
medication. However, controlled studies investigating the efficacy of this combined treatment 
strategy are scarce. Rothbaum et al. (2006) examined the effect of adding prolonged exposure 
for selective serotonin reuptake inhibitors (SSRIs) non-responders (48). PTSD were provided with 
10 weeks of open-label sertraline and those who did not remit were then randomized to either 
receive five additional weeks of sertraline alone or with 10 sessions of twice weekly prolongued 
exposure. Results show that the addition of 10 sessions led to increased treatment gains but only 
for patients who showed a partial response to phase I sertraline treatment. Prolongued exposure 
augmentation was associated with lower PTSD severity score, more remitters at 6 month follow-
up, and maintenance of treatment gains. In an similar design, no beneficial effects were found 
for paroxetine enhacement when given in addition to prolongued exposure to exposure refractory 
patients (49). In contrast, it was found that when the combination of exposure therapy and 
paroxetine (an SSRI) was provided from the beginning of treatment, it was more effective than 
exposure therapy plus placebo, implying additive benefits. However, the additive benefits 
disappeared by follow-up. Even though initial treatment with exposure therapy and paroxetine 
may lead to good clinical outcome, there are also some important disadvantages of this 
combination strategy, such as adverse events of medication, higher treatment costs, lower 




The SSRIs paroxetine and sertraline are currently the only medications approved by the 
European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in the USA. 
However, not all patients with PTSD respond to the SSRIs, leading to the need for augmentation 
or combination treatment strategies, and to interest in agents such as tiagabine or MDMA that 
employ novel mechanisms of action. The main outcome measure on randomized clinical trials 
(RCTs) is the impact on the Clinician Administered PTSD Scale (CAPS), the gold standard 
assessment scale. 
7.3.1. PHARMACOTHERAPY FOR PTSD 
Below there is a review of the findings of RCTs of pharmacotherapy for PTSD: 
• Monoamine oxidase inhibitors (MAOIs) 
The MAOIs were one of the first class agents to be tested in RCTs for treating PTSD. The 
monoamine oxidase A enzyme is a deaminator of both noradrenalin and serotonin, 
neurotransmitters that have been implicated in PTSD. 
• Reversible inhibitors of monoamine oxidase A (RIMAs)  
The development of RIMAs overcame many of the factors limiting the clinical utility of MAOIs, 
such as their potential for serious drug-related adverse events and stringent dietary 
restrictions that reduced the likelihood of compliance. Nevertheless, results were 
disappointing (51). 
• Selective serotinin reuptake inhibitors (SSRIs)  
The SSRIs represent the most frequently investigated class of agents in placebo-controlled 
trials of PTSD. 
o Paroxetine: paroxetine is registered by the EMA and the FDA for the short-term 
treatment of PTSD. All published randomized placebo-controlled trials of this 
medication have reported favourable results (52). 
o Fluoxetine: a placebo-controlled trial comparing treatment with 20 or 40 mg/d 
fluoxetine in a sample composed primarily of women did not detect superiority 
of medication after 12 weeks between any of the comparison groups (n=411) 
(53). 
o Sertraline: sertraline is registered by the EMA and the FDA for the short-term 
treatment of PTSD. It was suggested that sertraline was a safe, well-tolerated, 
and effective treatment for PTSD after only 2 weeks of sertraline treatment in 
187 patients (54). In contrast, there is a RCT of sertraline for PTSD that did not 
detect significant differences between sertraline and placebo on any of the 
primary or secondary efficacy measures at endpoint, and in consequence 
sertraline was not demonstrated to be efficacious in the treatment of PTSD in 




The limited evidence reviewed above suggests that treatment with SSRIs may be beneficial 
over the long term. However, a large portion of patients with PTSD fail to respond to treatment 
with pharmacotherapy, and few trials of pharmacotherapy in non-responders to first-line 
treatments for PTSD have been conducted, the majority of them add a course of antipsychotics 
to ongoing treatment with SSRIs. In general, findings from trials of PTSD appear to support the 
efficacy of this strategy, at least with respect to combat-related traumas. There is less evidence 
regarding the management of PTSD in civilian populations.  
There is evidence that prazosin, an 1-adrenergic antagonist, appears to be a promising 
and well-tolerated agent for the management of PTSD-related nightmares and sleep-related 
symptoms (56). For refractory cases, olanzapine was found to significantly reduce CAPS scores 
in the only RCT evaluating it, and risperidone was only effective in 1 of 3 studies (57). There is 
little empirical support for the efficacy of benzodiazepines in the treatment of PTSD, and contrary 
to expectations, the early administration of benzodiazepines to trauma survivors with high levels 
of initial distress did not have a salient beneficial effect on the course of their illness (58). 
Medication appears to alleviate PTSD symptoms associated with sympathetic hyperarousal 
and intrusive recollections of the trauma but seems ineffective against avoidant symptoms. 
Pharmacotherapy alone is rarely sufficient to provide complete remission of PTSD. Symptom relief 








8. CLINICAL TRIALS ASSESSING MDMA IN PTSD 
 
New research has shown that MDMA, used as a catalyst in psychotherapy, is effective in 
treating post-traumatic stress disorder. In the mid-1990s, the majority of research done on MDMA 
was focused on the potential dangers of the drug because it was categorized as a Schedule I 
drug. This legislation caused all clinical research to be terminated or severely restricted while the 
illicit use continued. Also, the therapists that were using MDMA in their practices were either 
forced to discontinue using the drug with their clients or ignore the law and risk legal punishment. 
Many studies found that MDMA had neurotoxic effects in animal models and in human 
retrospective studies. However, some of the erroneous beliefs about MDMA revolve around flawed 
studies or involved heavy drug abusers. Although there are risks involved with the use of any 
drug, the FDA has already concluded that MDMA has an acceptable risk to benefit ratio in a clinical 
setting. 
It was not until 2008 when the first RCT data on MDMA in PTSD was published. The world's 
first clinical trial to evaluate the safety and effectiveness of MDMA-assisted psychotherapy was a 
Spanish study that started in 2000, carried out by José Carlos Bouso in Madrid. This first study 
was designed as a randomized, double-blind, placebo-controlled trial assessing five dosages of 
MDMA in combination with psychotherapy: 50 mg, 75 mg, 100 mg, 125 mg, 150 mg (60), in 
patients with PTSD caused by sexual assault. Six of the 29 subjects were treated before pressure 
from the Madrid Anti-Drug Authority led to the revocation of permission to use the study site. As 
of May 13, 2002, when the study was shut down for political reasons, they had completed treating 
four patients in the 50 mg dose group (three patients received 50 mg and one received placebo), 
and two people in the 75 mg dose group (one patient received 75 mg and one received a 
placebo). All underwent 7 psychotherapy sessions of 90 minutes' duration, with only 1 session 
accompanied by MDMA or placebo. This psychotherapy session (session 4 of 8) began with MDMA 
ingestion and lasted for 6 hours, with patients resting for 2 additional hours after this 
psychotherapy session before being driven home. The overall Severity of Symptoms Scale for 
PTSD (SSSPTSD) scales score, the main outcome, reduced by an average of 26.8% with MDMA 
plus psychotherapy (60). 
This previous study was sponsored by the Multidisciplinary Association for Psychedelic 
Studies (MAPS). Founded in 1986, MAPS is a non-profit research and educational organization 
that develops medical, legal, and cultural contexts for people to benefit from the uses of 
psychedelics and marijuana. Their highest priority project is funding clinical trials of MDMA-
assisted psychotherapy for the treatment of PTSD, and also for anxiety associated with life-
threatening illness and social anxiety in autistic adults. MAPS is currently the only organization in 
the world funding clinical trials of MDMA-assisted psychotherapy. Below are shown the completed, 





8.1. COMPLETED STUDIES AND RESULTS 
The first study carried out in 2010 by the investigator Michael Mithoefer, when the Drug 
Enforcement Administration (DEA) informed that it had approved his Schedule 1 license. It was 
a randomized, double-blind, placebo-controlled trial assessing the impact of 125-mg MDMA-
assisted psychotherapy in refractory patients with PTSD (61). The subjects that met all enrollment 
criteria were 20, aged 21-70 years, with replacement of two dropouts. They were required to 
meet DSM-IV-R criteria for the diagnosis of crime or war-related chronic PTSD, and to have 
treatment-resistant symptoms, defined as a CAPS 50 (signifying moderate to severe symptoms), 
following at least 3 months of prior SSRI or serotonin-noradrenalin reuptake inhibitor (SNRI) 
treatment in addition to at least 6 months of psychotherapy. Patients underwent 11 regular 
nondrug psychotherapy sessions of 90 minutes' duration along with 2 MDMA 125-mg or inactive 
placebo sessions, in a ratio of 60% MDMA (n=12) to 40% placebo (n=8). The blind was broken 
for each subject after the follow-up visit 2 months after the second experimental session, and all 
subjects who initially received placebo were offered participation in an open-label crossover 
segment. Subjects were required to abstain from all psychotropic medication during study 
participation except sedative hypnotics or anxiolytics used as-needed between MDMA or placebo 
sessions. After preliminary evidence of safety and efficacy had been established, a protocol 
amendment was approved allowing the last nine subjects to receive a supplemental dose of 
MDMA or placebo in all experimental sessions. The purpose of that was to prolong the therapeutic 
window of MDMA effects and gather pilot data about dose for design of future clinical trials.  
The primary outcome was the CAPS score, a widely used structured interview for 
quantifying PTSD symptoms (62), and secondary outcomes measures were the Impact of Events 
Scale-Revised (IES-R), a 22-item self-report measure that assesses subjective distress caused by 
traumatic events (63), and the Symptom Checklist 90-Revised (SCL-90-R), a brief self-report 
psychometric instrument design to evaluate a broad range of psychological symptoms of 
psychopathology. Blood pressure, pulse and temperature were monitored during all experimental 
sessions, and also neurocognitive measures such as tests of attention and processing speed, 
expressive language, visual-spatial and constructional abilities, and memory.  
The experimental sessions lasted 8-10 h, followed by an overnight stay, with a male and a 
female co-therapist team present for all sessions, one a psychiatrist, the other a psychiatric nurse. 
The first dose of MDMA or placebo was given in a capsule by mouth at 10a.m. Subjects then 
rested in a comfortable position listening to a program of music that was initially relaxing and 
later emotionally evocative. Throughout the experimental sessions, periods of conversation 
alternated with periods during which subjects were encouraged to focus on introspection. The 
optional supplemental dose of 62.5 mg MDMA or placebo was administered 2-2.5h after the initial 
dose. The therapists stayed with the subject until at least 5p.m. or until the physical and 
psychological effects of the session had substantially subsided and the subject was judged to be 




a peak at 2-2.5h and lasted 4-5h in the 11 subjects who received a single dose, and 5-6h in the 
nine who received a supplemental dose. Effects diminished gradually over several hours, and 
elevations of blood pressure, pulse, and body temperature were greater in the MDMA group. 
There were no resulting medical complications, and the side effects that occurred more 
frequently in the MDMA group on the day of experimental sessions were: jaw tighness, nausea, 
feeling cold, dizziness, loss of appetite, and impaired balance. However, more common effects in 
the placebo group on the day of experimental sessions were: anxiety, insomnia, headache and 
fatigue. In the week following experimental sessions, some of the most common side effects 
were reported at similar incidence by both groups: fatigue, anxiety, low mood, headache and 
nausea, with anxiety being slightly more frequent in the MDMA group and low mood slightly more 
frequent in the placebo group. During this week, irritability and loss of appetite were more 
frequently reported in the MDMA group, and insomnia was reported more often in the placebo 
groups. Side effects typically resolved over a period of hours or days, usually spontaneously, 
sometimes with short-term symptomatic treatment, but no medical treatment was required 
during any experimental sessions nor serious drug-related adverse effects occurred.   
Figure 6. IES-R Mean Scores by Group for  
  Time 1-Time 4 (61) 
 
Figure 5. CAPS Mean Scores by Group for Time 1-Time 4 (61) 
PTSD symptoms measures by CAPS improved over time in both groups, as it shows Figure 5, but 
the MDMA group showed significantly greater improvement. Similar results were found for the 
IES-R, shown in figure 6, that improved over time in both groups but the MDMA group also 




from baseline in CAPS total severity score, and by the report that all three subjects who had been 
unable to work because of PTSD were able to return to work. In the first stage, the clinical 
response was 83.3% (10/12) in the MDMA group, versus 25% (2/8) in the placebo group, and 
10 subjects of the MDMA group no longer met DSM-IV criteria for PTSD, compared with 2 of the 
placebo group. Seven of the eight placebo subjects chose to enroll in the crossover arm, and 
showed significant decreases in CAPS (Table 2) and IES-R scores from end of the control trial to 
4-6 weeks after two MDMA sessions were completed.  
Table 2. Crossover Post-hoc Group Comparisons of CAPS at Time 1c- Time 4c (61) 
Crossover 
Arm 
CAPS Time 1c (Baseline)* Time 4c** Change Time 1c-Time 4c 
MDMA 
Mean 65.5 33.9 -31.7*** 
n 7 7 7 
Std. Dev. 24.3 12.8 15.0 
*Crossover Time 1c is pre-MDMA and at least 2 months post-placebo  
**4-6 weeks after second MDMA session 
*** p<0.05 Post-hoc paired t-test determined statistical significance of mean difference between times 
 
This study demonstrated that MDMA-assisted psychotherapy with close follow-up 
monitoring and support can be used with acceptable and short-lived side effects in carefully 
screened group of subjects with chronic, treatment-resistant PTSD. In this group, MDMA-assisted 
psychotherapy with inactive placebo produced clinically and statistically significant improvements 
in PTSD symptoms measured by standard symptom scales. This difference was immediate and 
was mantained throughout the time period.  
However, the study had several limitations and should be considered only a preliminary 
step toward exploring MDMA as a possible therapeutic adjunct. For example, the sample size was 
small as is appropiate in a Phase II pilot study, where there should be less than 400 people but 
more than 100. The majority of participants were female and all were caucasican, and gender/or 
ethnic differences in response to MDMA-assisted psychotherapy could exist. In fact, there is 
limited data about whether or not patients with war related PTSD are more difficult to treat than 
those with PTSD from other causes, such as sexual assault. Furtermore, at baseline, the placebo 
group had history of more prior psychotherapy than the MDMA-treated group, which could mean 
that the placebo group was more treatment-resistant. 
The second study by Michael Mithoefer reported follow-up data evaluating the long-term 
outcomes for the first completed trial of MDMA for chronic, treatment-resistant PTSD (6). All of 
the 19 subjects who received MDMA-assisted treatment in the original trial participated in the 
long-term follow-up (LTFU), with 16 out of 19 completing all the long-term outcome measures, 
which were administered from 17 to 74 months after the original study's final MDMA session. The 
CAPS, as in the original trial, remained the primary outcome measure, and the IES-R was used 




evaluations of MDMA-assisted psychotherapy, designed specifically to capture the perceived 
benefit or harm of MDMA-assisted psychotherapy and changes in any areas not addressed by 
standard outcome measures, such as changes in relationships or creativity. Additionally, the 
questionnaire included items addressing participant beliefs concerning the potential benefit of 
receiving an additional MDMA-assisted psychotherapy session, any psychiatric treatment after the 
study, and their use of "ecstasy" and/or any other illicit psychoactive substances plus any 
perceived changes in cognition after study participation. It was found that the mean CAPS and 
IES-R scores at LTFU for the 16 study completers were not statistically different from their 2-
month (short-term) mean scores, as it can be seen in Tables 3 and 4. At LTFU, two subjects had 
CAPS scores above 50, which indicates relapse with moderate-to-severe PTSD symptoms. 
Table 3. Early final study CAPS, 2 months after two MDMA-assisted sessions, versus the LTFU scores 
obtained in this study, for the same subjects. 
CAPS n Mean SD t df p 
2-month 16 24.6 18.6 
0.1 15 .91 
LTFU 16 23.7 23.7 
Table 4. Early final study IES-R, 2 months after two MDMA-assisted sessions, versus de LTFU scores obtained 
in this study, for the same subjects. 
IES-R n Mean SD t df p 
2-month 16 19.8 19.5 
0.4 15 .72 
LTFU 16 22.1 21.8 
In the LTFU questionnaire, all subjects reported a benefit from participation in the study, 
with at least some benefit persisting, and described the experimental treatment as being helpful, 
but also being difficult at times. At the time of enrollment, 16 of 19 study participants were in 
active psychotherapy. At LTFU, only 8 of 19 were in psychotherapy, being cognitive behavioral 
psychotherapy and EMDR the most common types. These results indicated that there was a 
favorable long-term risk/benefit ratio for PTSD treatment with just a few doses of pure MDMA 
administered in a supportive setting, in conjunction with psychotherapy. 
The third study, by Oehen et al. (2013) (64) was a randomized, double-blind comparison 
of psychotherapy assisted by low-dose MDMA (25mg + 12.5-mg supplementary dose) versus 
high-dose MDMA therapy (125mg + 62.5-mg supplementary dose) during three experimental 
doses interspersed with weekly non-drug-based psychotherapy sessions, enrolling 12 patients for 
treatment. All subjects who were enrolled met the DSM-IV-text revision criteria for PTSD with 
treatment-resistant symptoms, as was indicated by CAPS score of 50 and having previously 
undergone at least 6 months of psychotherapy and 3 months of treatment with an SSRI. Subjects 
were required to stop all psychotropic medication before entering the study. One female subject 
could not complete de 12-month follow-up because she died 6 months after finishing the MDMA-




had been in breast cancer remission for over 10 years. In the first stage, eight subjects were 
randomized in a double-blind manner to the full dose and four to the "active placebo" condition 
(2:1) to better assess the safety of the full dose and to enhace recruitment efforts. The outcome 
measures included two measures of PTSD symptoms: the CAPS scale and the Posttraumatic 
Diagnostic Scale (PDS), a validated self-reporting measure to asses the presence of PTSD 
symptoms. The psychotherapy used in the sessions was the same as Michael Mithoefer (61).  
 
Figure 7. Study visits 
The results showed the average CAPS scores in the "active placebo" increased slightly from 
T1 to T2 as shown in Figure 8. The high-dose group showed a distinct decrease in CAPS scores 
with time as compared to the active placebo group, but missed statistical significance. On 
average, CAPS scores decreased 15.6 points in the full-dose subjects. PDS scores decreased in 
the full-dose group (Figure 8), as compared to an increase in the "active placebo" group. Clinical 
response was observed in four out of eight subjects in the full-dose group, with all of them 
fulfilling PTSD criteria, but with a reduction in severity. Three full-dosage subjects met criteria for 
being non-responders and they were enrolled in "Stage 3", receiving either a full or higher dose 
of MDMA, but additional sessions did not lead to any further improvements in CAPS scores.  
In the "Stage 2" crossover group, all four subjects responded to the treatment, two of four 
subjects no longer fulfilled PTSD criteria and two had improved, but still had moderate PTSD. At 




in the full-dose group, while there was a 35-point decrease in the crossover group, with nine 
subjects showing a significant clinical improvement.  
 
Figure 8. CAPS and PDS scores by groups for time T0-T2 (64) 
Also at LTFU, five of 12 subjects no longer met the diagnostic criteria for PTSD, two had 
switched to having mild PTSD, and four had moderate PTSD, while one had died of a cause not 
related to the study. One of four subjects on disability and three who were fit for limited 
employment at baseline had been able to return to work full-time by the 1-year follow-up. A 
comparison of the safety profiles between 25mg and 125mg doses did support that the 125mg 
dose was associated with more drug-related reactions in general.  
The fourth study got the final approved study protocol in April 25, 2015 by the Israeli 
Ministry of Health. It has been taking place in Beer Ya'akov Mental Hospital, Israel by the principal 
investigator Moshe Kotler (65). The study is a randomized, double-blind, active placebo-controlled 
Phase 2 Pilot Study that investigates the safety and efficacy of MDMA-assisted psychotherapy in 
10 people with chronic, treatment-resistant PTSD. It includes and open-label lead-in in two 
subjects followed by a randomized, double-blind arm comparing 125 vs. 25mg MDMA in eight 
participants, and an open-label arm for participants who received active placebo during two 




weeks apart. The extent of PTSD symptoms were assessed at baseline, and two months after the 
second experimental session using a self-report mesure. Subjects enrolled in Stage 1 who 
received the active placebo, had the opportunity to enroll in Stage 2 of the protocol and complete 
open-label experimental sessions with the fully active dose of MDMA on the same schedule as 
Stage 1 and were assessed 12 months after the second Stage 2 experimental session. This study 
allows comparison between the impact of active placebo and full dose MDMA on PTSD symptoms, 
and on symptoms of depression and sleep quality. Latest news are that on November 10 and 
November 28, 2016, the fifth and sixth of 10 participants completed their 12-month follow-up 
interviews. 
The fifth completed study investigated the effectiveness of MDMA-assisted psychotherapy 
for PTSD when one member of the standard male/female co-therapist team is a healthcare intern 
(being trained in therapy, social work, or nursing) (66). The other member of each team is a 
professional therapist trained in the MAPS treatment method. The principal investigator is 
Marcelona Ot'alora, and is being developed in Boulder, Colorado. This Phase 2 pilot study 
examines the safety and efficacy of manualized MDMA-assisted psychotherapy in 23 subjects with 
chronic, treatment-resistant PTSD of at least six months duration who were unable to achieve 
remission despite having received prior treatment with either pharmacotherapy or psychotherapy 
of adequate dose/duration or who discontinued treatment due to lack of tolerability. Two types 
of co-therapist teams conducted the study. Each team had an experienced therapist with a 
background consistent with that required in the treatment manual paired with either another 
experienced therapist or an "intern" co-therapist that is either pre-licensure, is licensed but with 
less experience, has a different therapy background than indicated in the manual, or practices a 
different healing profession (physician, nurse, social worker). On February 24, 2017, investigators 
gathered for the formal closeout of the study, and all treatment sessions and long-term follow-
up interviews have now been completed. The final results are being prepared for publication.  
The sixth completed Phase 2 pilot study is a randomized, double-blind, placebo controlled 
study in 12 subjects that estimates the effect sizes of full dose and comparator dose MDMA as 
an adjunct to manualized psychotherapy by the principal investigator Ingrid Pacey in Vancouver, 
Canada (67). The study is officially completed and investigators gathered for the formal closeout 
on November 27, 2016. The final results are being prepared for publication. 
The final results of the last two studies are being prepared for publication as a part of a 
global meta-analysis of MDMA-assisted psychotherapy results by MAPS.  
8.2. ONGOING STUDIES  
Encouranging data has been obtained and submitted to the FDA from MAPS's completed 
studies, and MAPS is currently sponsoring other Phase 2 studies all over the world (68). 
The first study will investigate the effects of MDMA on startle testing learning in health 
volunteers in comparison a placebo control. This study will be conducted by the principal 




The second study is a "Training protocol for MDMA-assisted psychotherapy" by the principal 
investigators Michael Mithoefer, Ann Mithoefer and Marcela Ot'alora. This Therapist 
Training/Phase 1 psychological effects protocol is a placebo-controlled, double-blind, randomized, 
cross-over study that allows MAPS to administer a single MDMA-assisted psychotherapy session 
to therapists as part of their training to conduct MAPS' MDMA/PTSD studies, while also conducting 
a series of evaluations of the psychological effects of MDMA administered to healthy volunteers 
in a therapeutic context.  
The third MDMA-assisted psychotherapy study is a Phase 1/2 open-label treatment 
development study of MDMA-assisted CBT integrated with MDMA-assisted psychotherapy for the 
treatment of PTSD. This study will enroll 10 pairs consisting of one participant diagnosed with 
PTSD, and one concerned significant other who does not have a current PTSD diagnosis but who 
is experiencing problems associated with the psychosocial circumstances related to the PTSD 
participant's diagnosis. The primary outcome measure is the CAPS scale according to DSM-5 
administered to the participant with PTSD but additional measures evaluate the qualities of the 
relationship between the participants, and psychological distress in the significant other.  
Nowadays, there is one planned study by MAPS that will evaluate the safety and 
effectiveness of MDMA-assisted psychotherapy in 12 subjects with chronic, treatment-resistant 
PTSD in Australia. Seven subjects will be allocated to the full dose condition (125mg with a 
supplemental 62.5mg), with the remaining five to the low dose condition (30mg with a 
supplemental 15mg). The study is in the protocol approval stage.  
All studies presented take part in the main goal of MAPS, that is undertaking a $25 million 
plan to make MDMA into a FDA-approved prescription medicine by 2021. Ongoing and planned 
Phase 2 studies are laying the groundword for an eventual End-of-Phase 2 meeting with FDA and 
possible Phase 3 multi-side MDMA/PTSD research studies.  
8.3. DISCUSSION 
The psychopharmacology of MDMA has been extensively studied over the past 20 years as 
it is presented in this paper work. However, attemps by scientists and the government to show 
the neurotoxic effects in humans have only produced equivocal results. For many years, MDMA 
research had been biased towards showing the neurotoxic effects of the drug while ignoring the 
clinical applications because just as the drug was becoming well known in the clinical sphere, it 
was also being used recreationally before the neuroscientific mechanisms of this property could 
be investigated, unfortunately. Moreover, neurotoxicity of MDMA has only been reported in heavy 
abusers or in animal models using high and repeated doses (69). 
Furthermore, a large number of different classes of psychoactive drugs like MDMA are 
controlled under national laws. This is supposedly aimed to reduce the use of the drug because 
of the harms it cause, even though in many cases these harms may be less than those of some 




on MDMA neurotoxic effects, the underlying mechanisms of neurotoxicity still remain to be fully 
elucidated.  
The use of Schedule I substances, such as MDMA, is to be severily restricted, and this 
means that research using these substances can be undertaken only after approval of a 
government agency. As a consequence, many researchers who would like to work on this 
substance can not afford to do so. For example, it took more than 4 years to obtain approvals to 
import MDMA from Switzerland for the Oehen et al. (2013) trial, even after Health Canada had 
approved the protocol design. So, the approach of putting penalization of illegal drug posession 
has severily limited neuroscience research and the discovery of new treatments for brain disorders 
in general. If MDMA achieves its status as potential therapeutic agent, it would have to be moved 
to a lower Schedule in the drugs legislation, that is less restrictive and would make it much more 
accessible for research.  
It is important to note that MDMA is thought to be a therapeutic catalyst rather than a 
"cure" for PTSD. Non-drug psychotherapy sessions are conducted before and after the MDMA-
assisted psychotherapy. The initial non-drug sessions are to prepare the patient for the MDMA 
experience, while the follow-up sessions are used to solidify any insight gained or alleviate any 
difficulties experienced during the drug therapy sessions. A wide range of psychopathological 
scales are being used in order to measure not only PTSD symptoms, but also its associated 
comorbidities such as anxiety, depressions, phobias, maladjustment and damaged self-steem. 
Blood pressure, heart rate and other somatic side effects are also being assessed and til now 
they have showed no significant elevation, suggesting that the doses administered were 
psyshiologically safe. Low doses of MDMA administered as an adjunct to psychotherapy are found 
to be safe and there are promising signs of efficacy and reduced PTSD symptomatology. 
Most of the clinical trials carried out added LTFU of the study subjects who received MDMA-
assisted psychotherapy, as an amendment to an initial study design. Because it is not practical 
nor ethical to mantain a placebo group for over a year, nor to control for other treatments for 
that period of time, this limitation is commonly found in LTFU studies. In light of this limitation, 
it is possible that the favourable results of the LTFUs study were caused by resolution of 
symptoms due to natural history or to other variables that were not controlled for after the follow-
up. Evaluation of longer-term outcomes may contribute significantly to the understanding and 
treatment of chronic mental illnesses like PTSD and their associated morbidity and disability. For 
example, LTFU studies could help to formulate treatment guidelines, permit evaluation of the 
rates of sustained symptom reduction or remission, predict the need for maintenance treatment, 
permit the assessment of long-term tolerability and help rule out a placebo response.  
Practice guidelines for the treatment of PTSD accept the need for replication of previous 
studies, as well as the need for novel treatments, more specifically pharmacological agents that 




size and with the administration of higher doses of MDMA are clearly needed in order to clarify 
both the safety and the efficacy of MDMA-assisted psychotherapy in patient populations.  
In my opinion, the use of MDMA plus psychotherapy can be helpful in PTSD-treatment, 
because increased interpersonal closeness may permit patients to explore upsetting thoughts, 
memories or feelings. Facilitated recall and unusual and potentially innovative shifts in thinking 
and perception could contribute to generating new perspectives about past or current thoughts, 
feelings and experiences. It is important to remember that trauma may lead to severe distress 
and considering the high rate of comorbid depression in PTSD patients, the negative mood post-
MDMA intake calls for caution. Implementation in routine clinical care is further complicated by 
the need for physical monitoring during MDMA enhacement, especially with its known cardiac 
effects. And notably, the use of MDMA as an adjunctive to treatment is not without controversy, 
as its use as a recreational drug is criminalized in most countries, and because of its Schedule-I 
category, that makes it more difficult to study.  
Even though there are questions regarding safety and tolerability of MDMA, clinical results 
showed that MDMA-assisted psychotherapy was safely administered with no drug-related serious 





MDMA acts mainly on the monoaminergic system, and it also produces oxytocin release, 
which improves bonding and raises levels of empathy.    
MDMA-assisted psychotherapy is a promising therapy for refractory PTSD. It possesses 
unique pharmacological and psychological properties that may make it specially well suited for 
use as an adjunct to psychotherapy. It facilitates the communication and connection with the 
psychotherapists, increases the positive mood, increases access to emotionally intense material 
and compassion for the self and others.  
Now that safety parameters for limited use of MDMA in clinical settings have been 
established, a case can be made to further develop MDMA-assisted therapeutic interventions that 
could support social anxiety or similar types of distress. 
Preliminary results from clinial trials show that MDMA-assisted psychotherapy with close 
follow-up monitoring and support can be used with acceptable and short-lived side effects in a 
carefully screened group of subjects with chronic, treatment-resistant PTSD. 
Even though clinical trials show promising results and benefits are appreciable over the 
long term, there are methodological weaknesses, and are not definitive.  
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